S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
"The Bull Market Is Officially OVER"  (Ad)pixel
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
"The Bull Market Is Officially OVER"  (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
"The Bull Market Is Officially OVER"  (Ad)pixel
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
"The Bull Market Is Officially OVER"  (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
"The Bull Market Is Officially OVER"  (Ad)pixel
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
"The Bull Market Is Officially OVER"  (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
"The Bull Market Is Officially OVER"  (Ad)pixel
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
"The Bull Market Is Officially OVER"  (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:ARAV

Aravive - ARAV Stock Forecast, Price & News

$1.46
+0.08 (+5.80%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.30
$1.46
50-Day Range
$0.78
$2.09
52-Week Range
$0.58
$3.13
Volume
82,296 shs
Average Volume
261,824 shs
Market Capitalization
$87.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

Aravive MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
430.8% Upside
$7.75 Price Target
Short Interest
Healthy
0.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
0.17mentions of Aravive in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.87) to ($1.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

210th out of 1,034 stocks

Pharmaceutical Preparations Industry

85th out of 502 stocks

ARAV stock logo

About Aravive (NASDAQ:ARAV) Stock

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

ARAV Stock News Headlines

Short Interest in Aravive, Inc. (NASDAQ:ARAV) Rises By 76.9%
See More Headlines
Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

ARAV Company Calendar

Last Earnings
10/27/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARAV
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.75
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+333.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-39,150,000.00
Net Margins
-695.57%
Pretax Margin
-695.57%

Debt

Sales & Book Value

Annual Sales
$7.44 million
Book Value
$0.25 per share

Miscellaneous

Free Float
36,255,000
Market Cap
$87.35 million
Optionable
Optionable
Beta
2.37

Key Executives

  • Dr. Fredric N. Eshelman Pharm.D. (Age 73)
    Exec. Chairman
    Comp: $95k
  • Dr. Gail F. McIntyre CH (ASCP) (Age 59)
    DABT, Ph.D., Pres, CEO & Director
    Comp: $699.7k
  • Dr. Jeffrey L. Cleland Ph.D. (Age 57)
    Co-Founder
  • Dr. Joshua Silverman Ph.D.
    Co-Founder
  • Mr. Rudy C. Howard B.A. (Age 64)
    CPA, CPA, Chief Financial Officer
  • Dr. Leonard Scott Dove Ph.D. (Age 49)
    Chief Operating Officer
  • Mr. Marek Ciszewski J.D.
    VP of Investor Relations
  • Dr. Randy L. Anderson
    Sr. VP of Data Sciences
  • Dr. Robert B. Geller M.D. (Age 68)
    Chief Medical Officer
  • Kenneth L. Guernsey
    Sec.













ARAV Stock - Frequently Asked Questions

Should I buy or sell Aravive stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARAV shares.
View ARAV analyst ratings
or view top-rated stocks.

What is Aravive's stock price forecast for 2023?

4 Wall Street research analysts have issued 12 month price targets for Aravive's shares. Their ARAV share price forecasts range from $2.00 to $12.00. On average, they expect the company's stock price to reach $7.75 in the next twelve months. This suggests a possible upside of 430.8% from the stock's current price.
View analysts price targets for ARAV
or view top-rated stocks among Wall Street analysts.

How have ARAV shares performed in 2022?

Aravive's stock was trading at $2.19 at the start of the year. Since then, ARAV shares have decreased by 33.3% and is now trading at $1.46.
View the best growth stocks for 2022 here
.

Are investors shorting Aravive?

Aravive saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 530,000 shares, an increase of 76.9% from the October 31st total of 299,600 shares. Based on an average daily volume of 627,000 shares, the short-interest ratio is currently 0.8 days.
View Aravive's Short Interest
.

When is Aravive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ARAV earnings forecast
.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) posted its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.07. The business earned $2.41 million during the quarter, compared to analyst estimates of $2.36 million. Aravive had a negative trailing twelve-month return on equity of 190.16% and a negative net margin of 695.57%.

What other stocks do shareholders of Aravive own?
What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.39%), BlackRock Inc. (0.59%) and Two Sigma Advisers LP (0.14%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends
.

How do I buy shares of Aravive?

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $1.46.

How much money does Aravive make?

Aravive (NASDAQ:ARAV) has a market capitalization of $87.35 million and generates $7.44 million in revenue each year. The company earns $-39,150,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com.

This page (NASDAQ:ARAV) was last updated on 12/4/2022 by MarketBeat.com Staff